A federally funded study surveyed 315 adults over 65 around New York City parks and senior centers. More than half had used cannabis at some point. Twenty-two percent used it in the past year, 16 percent in the past month, and 11 percent within the previous 24 hours.
One in nine seniors, high yesterday. The generation raised on Reefer Madness and Just Say No is now walking into dispensaries.
That’s the cultural headline, but look at what else is in today’s feed and you’ll notice something else entirely. Insurance trade groups are asking Congress to let them underwrite dispensaries normally. California’s top regulator says the DEA wants state medical-cannabis data while providing almost no guidance in return. North Carolina is studying whether the state itself should own the stores. Illinois wants to move cannabis reparations from community grants to direct cash payments. Missouri recalled pre-rolls after random testing found mold. And Portugal’s 25-year decriminalization experiment has a lesson America keeps refusing to learn.
Nobody in any of those stories is debating whether marijuana should exist. They’re debating insurance, testing, distribution, tax allocation, and retail architecture. Cannabis has entered the plumbing phase, and plumbing is what determines whether an industry actually works. Let me walk you through it.
Seniors are a real cannabis demographic now, and not just for arthritis.
Researchers from UC San Diego and NYU surveyed 315 adults age 65 and older, mostly around public parks and senior centers in New York City. Fifty-six percent had used cannabis at some point in their lives, 22 percent within the past year, 16 percent in the past month, and 11 percent in the previous 24 hours.
The reasons complicate the stereotype. This isn’t purely older people seeking pain relief. Recreation matters too, with some consumers simply wanting to get high and others reporting medical or wellness motivations.
A 72-year-old doesn’t necessarily want cannabis branded like medicine. They also don’t want packaging designed for a 23-year-old at a festival. There’s an enormous product-design opportunity sitting in between, and almost nobody is building for it.
That gap is real: low-dose edibles, precisely dosed beverages, packaging that’s child-resistant but not impossible for arthritic hands, clearer typography, reliable ratios, predictable duration, and retail staff trained to discuss onset times and interactions without pretending to practice medicine. The healthcare piece deserves equal weight, because older consumers take more medications, and cannabis can interact with other drugs while affecting balance, cognition, and cardiovascular function. The industry can’t celebrate senior adoption and ignore that. There’s a commercial angle worth naming too, since older consumers hold considerable household wealth, and a market increasingly serving retirees looks less like a counterculture category and more like ordinary consumer goods. The demographic stereotype is collapsing, and political stigma usually follows stereotypes down.
🎯 The bottom line: Seniors may be cannabis’s most underestimated growth segment. But don’t treat them as frail patients or aging hippies. They’re consumers, some want relief, some want sleep, some just like it, and the brands that understand the difference will win.
Insurance companies are now lobbying Congress on behalf of cannabis.
Cannabis financial reform just picked up an unusual constituency. Not cannabis companies. Not advocacy groups. Insurers. A coalition of major insurance trade organizations is backing the Clarifying Law Around Insurance of Marijuana Act, the CLAIM Act, introduced by Reps. Nydia Velázquez and Warren Davidson with a Senate counterpart already filed. The bill would protect insurers, agents, and brokers from federal penalties for serving state-legal cannabis businesses.
Their argument is purely commercial: federal and state law conflict, that conflict creates liability and uncertainty, and a federal safe harbor would let them serve legitimate businesses without fearing regulatory punishment.
This is bigger than it sounds, and anyone who has worked a credit file knows exactly why.
A borrower can have strong statements, experienced management, workable coverage, and excellent collateral. Then the credit officer asks where the property insurance is, and cannabis suddenly becomes complicated. You can’t treat insurance as somebody else’s problem when the insured building is your collateral.
What happens if the facility burns, inventory is destroyed, a customer sues, equipment fails, or operations stop for three months after a disaster? Conventional businesses transfer those risks. Cannabis businesses have faced narrower options, higher pricing, and federal uncertainty. Which is why CLAIM belongs alongside banking reform rather than beneath it, because credit gets dramatically easier when ordinary risk-management products exist. The bipartisan structure helps, since the bill doesn’t require anyone to agree on federal legalization, just on a narrower question: if a state decided a business can legally operate, should the federal government interfere with insuring it? And there’s a discipline benefit people overlook, because underwriters inspect risk, caring about fire suppression, security, product liability, employee safety, construction quality, and inventory controls. Insurance doesn’t just pay out after something goes wrong, it pressures companies to prevent it.
🎯 The bottom line: Banking can’t normalize without insurance normalizing alongside it. You can’t build conventional commercial credit on unconventional risk protection, which may make this boring bill one of the most consequential in Congress.
California says the DEA wants its data but won’t explain its own rules.
Federal rescheduling has hit the stage every banker should watch: implementation. Clint Kellum, director of the California Department of Cannabis Control, told the state’s Cannabis Advisory Committee that California has received no formal implementation guidance from DEA headquarters despite attempting to communicate with the agency. Meanwhile, the DEA has requested information from California about medical cannabis production and dispensing.
Recall the sequence. In April, Attorney General Todd Blanche moved marijuana products under qualifying state medical licenses, plus FDA-approved marijuana drugs, from Schedule I to Schedule III. The DEA then opened a registration process, and now some businesses that registered are reportedly seeing inspections, with California officials saying the approach appears to vary by region and different operators may be getting different questions.
Ambiguity creates compliance risk for operators. It creates underwriting risk for lenders. Those are the same problem wearing different clothes.
Picture financing a medical cannabis borrower whose cash flow improves because Schedule III changed its federal tax treatment. Looks great, until you ask what the borrower must do to maintain federal eligibility, which registration applies, what documentation is required, what employee restrictions exist, what happens after an inspection, whether registration can be revoked, and how revocation would hit the tax status. Those become credit questions fast. California’s position is complicated because its market doesn’t cleanly separate medical and adult-use commerce the way some states do, so a number labeled “medical sales” may mean something entirely different where consumers have little incentive to formally register as patients. The state wants to understand how the DEA will interpret its data before handing it over, which is reasonable. The deeper problem is that America built state cannabis markets precisely because the federal government refused to build one, those systems evolved differently, and Washington is now trying to overlay federal controlled-substance regulation on top. The pieces don’t naturally fit.
🎯 The bottom line: Schedule III isn’t just a tax story anymore, it’s a regulatory architecture story. Federal legitimacy improves the economics and brings federal supervision, and the biggest risk right now may be operators trying to comply before anyone explains the rules.
North Carolina is studying government-owned weed stores.
North Carolina may eventually legalize, but it’s considering a structure that would look nothing like Colorado or Michigan. A subcommittee of the North Carolina Advisory Council on Cannabis is studying a model where private companies cultivate, manufacture, and distribute while the state controls retail sales, potentially including a centralized cannabis warehouse supplying government-operated stores.
Nationally that sounds strange. In North Carolina it isn’t, because the state already runs a government-controlled ABC system for liquor. Policymakers aren’t inventing state retailing, they’re asking whether cannabis should follow the alcohol architecture they already know. Governor Josh Stein created the council in 2025 with a mandate covering youth protection, public safety, adult access, agriculture, expungement, and reinvesting revenue into addiction treatment and mental health.
The advantages are obvious, since government would control store locations, age verification, product assortment, retail training, pricing, and consumer education, while limiting aggressive commercialization. For anyone worried about a dispensary on every corner, that’s appealing. The tradeoffs are just as real, because private dispensary operators would vanish from one of the industry’s most visible segments, competition could decline, innovation could slow, and government becomes both regulator and retailer, which creates its own conflicts.
Two states can both “legalize marijuana” and create completely different credit opportunities. In this model, retail lending barely exists, and financing clusters around cultivation, manufacturing, equipment, warehousing, transportation, and real estate instead.
Deposit flows also look different when the state collects retail revenue directly, which is why market design matters to financial institutions well before legalization happens. The centralized warehouse idea deserves scrutiny too, since it could create real efficiencies while concentrating risk in inventory management, security, testing, recalls, vendor payment, and technology, where one disruption affects the entire retail system. And this intersects with the state’s existing intoxicating-hemp market, because Stein created the council partly since THC products are already widely available with no coherent statewide structure. North Carolina isn’t choosing between cannabis and no cannabis. It’s deciding who controls commerce that already exists.
🎯 The bottom line: Legalization determines whether a market exists. Market structure determines who makes money from it, and banks should care about the second question as much as the first.
Pennsylvania is surrounded by legal markets and still arguing.
Pennsylvania’s cannabis politics are hard to explain geographically. New York, New Jersey, Maryland, and Ohio all have legal adult-use markets. Pennsylvania remains the major Northeastern holdout. Senate Democrats are restarting the conversation with a public hearing Friday, September 25 in Philadelphia, titled “Adult-Use Cannabis: Criminal Justice, Safety & Economic Impacts,” chaired by Sen. Nick Miller with longtime advocate Sen. Sharif Street participating.
The title tells you something. Pennsylvania has stopped debating cannabis solely as criminal justice and moved into enforcement, safety, economics, and record reform. Governor Josh Shapiro has repeatedly backed legalization and included it in his 2026-27 budget, contemplating legalization effective July 1 with regulated sales starting January 1, 2027 and more than $200 million in projected annual tax revenue at maturity.
But the state keeps failing to convert broad support into an agreed market structure, which is the actual problem.
Legalization is easy as a polling question. Implementation creates constituencies. Who gets licenses, private dispensaries or state stores, existing medical operators or new social-equity applicants? Those details decide who supports the final bill.
The leakage argument keeps getting stronger, since every Pennsylvania resident buying in a neighboring state represents economic activity the Commonwealth chose not to regulate. But lawmakers should resist building legalization around tax revenue alone, because cannabis taxes only work when consumers stay in the legal market. Set rates too high and illicit sellers keep a pricing edge, restrict licenses too tightly and prices stay elevated, over-license production and margins collapse. Sustainable legal-market capture first, revenue second. For lenders, Pennsylvania is one of the largest remaining East Coast opportunities, with nearly 13 million residents, major metros in Philadelphia and Pittsburgh, and established medical infrastructure. But wait for architecture before forecasting anything, because a state-controlled model produces a completely different lending landscape than private retail.
🎯 The bottom line: Pennsylvania doesn’t need another abstract argument about whether legalization works, since four neighbors are already running the experiment. The real question is what kind of market it wants.
Illinois wants to try cannabis reparations as direct cash.
Cannabis social equity usually flows through communities. Illinois is considering whether some should go straight to people. State Rep. La Shawn Ford introduced HB 5815, creating an Illinois Freedom Program making direct cash payments to qualifying people disproportionately affected by historical cannabis enforcement, sitting inside the existing Restore, Reinvest and Renew framework with a new Illinois Freedom Fund financing payments. The bill is written specifically not to cannibalize current R3 grants, stating it cannot reduce, delay, or reallocate revenue already going to existing grantees, relying instead on funding tied to growth in cannabis revenue, with a proposed effective date of July 1, 2027.
This is a philosophical shift. Social equity has generally meant expungement, licensing preferences, technical assistance, low-interest financing, and community grants. Direct compensation asks something different.
If prohibition inflicted measurable harm on specific people, why should repair flow only through organizations and business opportunities? A neighborhood grant doesn’t compensate the individual who lost employment, housing, education, or years of freedom.
The critics have equally legitimate questions though, and they’ll decide whether this becomes durable policy or symbolism. Who qualifies, an arrest or a conviction or incarceration or simply residence in an impacted area? How is harm measured, how large are payments, and what happens when cannabis-tax growth slows? The bill also exposes something important about legalization economics, because cannabis taxes now have competing constituencies in general funds, education, local government, public health, regulation, law enforcement, community reinvestment, and now direct compensation. Every additional promise complicates tax design, and governments fall into a predictable trap: build programs dependent on marijuana revenue, raise taxes to fund them, widen the gap between legal and illicit prices, weaken legal sales, and watch collections disappoint. Illinois has to balance restorative ambition against market sustainability, because the funding model can undermine itself.
🎯 The bottom line: Illinois is pushing social equity from abstraction toward a tangible question, should people harmed by prohibition receive money directly? That forces policymakers to define who was harmed, how harm is measured, and what repair actually means.
Missouri found mold in pre-rolls and recalled them. That’s the system working.
Missouri regulators recalled infused pre-rolls after random state testing detected aspergillus, a mold that poses risks particularly for immunocompromised consumers. The affected product is Juicy J’s cherry limeade infused pre-rolls, no adverse reactions have been reported, and the Missouri Division of Cannabis Regulation is working with the manufacturer.
A recall sounds like bad news for legalization. It’s actually one of its stronger arguments. The product was licensed, the state could identify it, testing occurred, regulators traced affected inventory, a recall was issued, consumers were warned.
An illicit pre-roll with mold in it doesn’t get recalled. A regulated one can. The existence of a recall doesn’t prove regulation failed, it proves a system exists to detect failure.
Missouri’s testing story matters more than the recall itself, because the state began independently double-checking licensed laboratories last year after concerns about inconsistent results. Previously obtained data showed one laboratory handling an unusually large share of Missouri cannabis testing while reporting an aspergillus failure rate far below both other Missouri labs and the national average. That’s lab shopping, one of the industry’s most persistent technical problems, because when labs produce different potency or contaminant results, operators have a financial incentive to use whichever one issues the most favorable certificate. A cannabis label is only worth something if consumers, regulators, and lenders can trust the number, which means testing integrity reaches well past public health into inventory valuation, product liability, insurance, brand reputation, and credit. A borrower hit with a major recall can lose revenue, inventory, retailer relationships, and consumer trust almost overnight. So quality systems belong in operational diligence: which labs does the borrower use, how often are products retested, any recall history, how is quarantine inventory handled, what product-liability coverage exists, how concentrated is revenue in one SKU, and is there enough liquidity to absorb a recall. Those are normal manufacturing-credit questions, and cannabis keeps getting treated as though product testing is a uniquely political burden. It isn’t.
🎯 The bottom line: The goal isn’t zero recalls. It’s a system that finds unsafe products fast, traces them accurately, and pulls them before anyone gets hurt. Weak operators dislike random testing. Strong ones should welcome it.
Portugal’s 25-year lesson: the statute was never the hard part.
Portugal decriminalized possession of drugs for personal use 25 years ago, and the world spent the next quarter-century arguing about the word decriminalization. The more important word was infrastructure. The 2001 reform didn’t legalize trafficking or create a free-for-all, it referred people caught with small personal quantities to multidisciplinary commissions that connect them to healthcare and social services or impose administrative sanctions. What changed was the decision to stop treating personal possession primarily as a criminal matter.
But Portugal didn’t stop at the law. It invested in treatment, healthcare, harm reduction, multidisciplinary care, housing support, and employment assistance. The reform emerged from a devastating heroin crisis, and drug-related deaths fell sharply afterward, with new HIV diagnoses tied to injection drug use dropping from 583 in 2005 to 19 in 2024, and more than 24,000 people receiving treatment through the specialized public outpatient system in 2023.
Those numbers usually get summarized as proof decriminalization works. The sharper reading is that a public-health approach works when government actually funds and maintains the public-health system required to deliver it.
That’s why importing Portugal’s model keeps failing. Oregon decriminalized through Measure 110 and British Columbia ran a pilot, neither built the infrastructure, backlash followed visible public drug use, Oregon recriminalized and BC’s pilot expired.
The uncomfortable part is that infrastructure is harder than legislation. A bill passes in an afternoon. Treatment capacity, trained staff, housing programs, clinical networks, harm-reduction services, and public trust take years. Cannabis policymakers should sit with that, because a state can legalize marijuana today and still not have banking, insurance, testing labs, competent regulators, reasonable tax policy, trained physicians, safe products, or sustainable businesses. All of it has to be built. North Carolina’s retail debate is infrastructure. Missouri’s recall system is infrastructure. The CLAIM Act is infrastructure. DEA guidance is infrastructure. Illinois’s Freedom Fund is infrastructure around prohibition’s social consequences. Which is why evaluating a state solely by whether it legalized tells you almost nothing about whether the market is any good, since California, Michigan, Illinois, and New York all legalized and their structures and outcomes differ enormously.
🎯 The bottom line: Portugal’s real innovation wasn’t removing penalties, it was replacing punishment with something. Legalization isn’t the finish line, it’s permission to start building.
Wednesday closing
Missouri is a useful place to end. A product failed testing, regulators recalled it, and that sounds mundane. It should. Normal industries have problems. Cars have defective parts, restaurants fail inspections, banks make bad loans, drug companies recall medicines. Failure isn’t what separates mature industries from immature ones. What separates them is whether a system exists to detect, contain, and correct it.
Look at today’s stories through that lens. Insurance is financial maturity. The California DEA dispute is regulatory maturity, even while it’s messy. North Carolina is market-design maturity. Pennsylvania is political maturity. Illinois is social-equity policy evolving. Missouri is consumer protection. The senior study is cultural. And Portugal shows what institutional maturity looks like after 25 years. None of it is primarily about whether someone should be arrested for possession, which is the progress. Cannabis spent decades demanding to be treated like every other industry, and here’s the part nobody printed on a protest sign: every other industry has insurance requirements, recalls, lender scrutiny, testing standards, federal agencies that communicate poorly, tax fights, and market-structure fights. Cannabis wanted normal. This is normal.
There’s a specific implication for anyone lending into this space. The risk model is shifting. Cannabis risk used to be dominated by one enormous variable, federal illegality, and that hasn’t disappeared. But as federal policy evolves, conventional business risks become relatively more important: management quality, margins, tax exposure, product liability, insurance, inventory controls, customer concentration, leverage, liquidity, operational discipline. That’s healthy. A good cannabis company should eventually get credit because it’s a good company, not because a bank happens to tolerate cannabis, and a bad one should fail because it’s badly run, not because marijuana is federally complicated. And notice that normalization isn’t a relaxation of standards, it’s usually an increase. Older consumers mean medication interactions matter more. Mainstream products mean labeling matters more. Bank involvement means financial controls matter more. Insurers mean safety matters more. Federal regulators mean documentation matters more. Portugal’s version of that lesson is the broadest one, that America keeps trying to copy policy outcomes without paying for institutional capacity. If you want legal cannabis, build competent regulators. If you want cannabis lending, build insurance access. If you want medical cannabis, build medical evidence. For years cannabis asked America for permission, and America is increasingly saying yes. The defining question now is whether the industry can build institutions strong enough that nobody has to treat it as a special case anymore.
That’s what this newsletter is for.
What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.
If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.